Mannino DM, Buist AS: Global burden of COPD: risk factors, prevalence, and future trends.
Lancet 2007,370(9589):765–773.
Article
PubMed
Google Scholar
Chartbook on Cardiovascular, Lung, and Blood Diseases
[http://www.nhlbi.nih.gov/resources/docs/cht-book.htm]
Hogg JC, Chu F, Utokaparch S, Woods R, Elliott WM, Buzatu L, Cherniack RM, Rogers RM, Sciurba FC, Coxson HO, Pare PD: The nature of small-airway obstruction in chronic obstructive pulmonary disease.
N Engl J Med 2004,350(26):2645–2653.
Article
CAS
PubMed
Google Scholar
Jeffery PK: Structural and inflammatory changes in COPD: a comparison with asthma.
Thorax 1998,53(2):129–136.
Article
CAS
PubMed
PubMed Central
Google Scholar
Barnes PJ, Pedersen S, Busse WW: Efficacy and safety of inhaled corticosteroids. New developments.
Am J Respir Crit Care Med 1998,157(3 Pt 2):S1–53.
Article
CAS
PubMed
Google Scholar
Hattotuwa KL, Gizycki MJ, Ansari TW, Jeffery PK, Barnes NC: The effects of inhaled fluticasone on airway inflammation in chronic obstructive pulmonary disease: a double-blind, placebo-controlled biopsy study.
Am J Respir Crit Care Med 2002,165(12):1592–1596.
Article
PubMed
Google Scholar
Sutherland ER, Allmers H, Ayas NT, Venn AJ, Martin RJ: Inhaled corticosteroids reduce the progression of airflow limitation in chronic obstructive pulmonary disease: a meta-analysis.
Thorax 2003,58(11):937–941.
Article
CAS
PubMed
PubMed Central
Google Scholar
Effect of inhaled triamcinolone on the decline in pulmonary function in chronic obstructive pulmonary diseaseN Engl J Med 2000,343(26):1902–1909.
Burge PS, Calverley PM, Jones PW, Spencer S, Anderson JA, Maslen TK: Randomised, double blind, placebo controlled study of fluticasone propionate in patients with moderate to severe chronic obstructive pulmonary disease: the ISOLDE trial.
BMJ 2000,320(7245):1297–1303.
Article
CAS
PubMed
PubMed Central
Google Scholar
Paggiaro PL, Dahle R, Bakran I, Frith L, Hollingworth K, Efthimiou J: Multicentre randomised placebo-controlled trial of inhaled fluticasone propionate in patients with chronic obstructive pulmonary disease. International COPD Study Group.
Lancet 1998,351(9105):773–780.
Article
CAS
PubMed
Google Scholar
Spencer S, Calverley PM, Sherwood Burge P, Jones PW: Health status deterioration in patients with chronic obstructive pulmonary disease.
Am J Respir Crit Care Med 2001,163(1):122–128.
Article
CAS
PubMed
Google Scholar
Valk P, Monninkhof E, Palen J, Zielhuis G, van Herwaarden C: Effect of discontinuation of inhaled corticosteroids in patients with chronic obstructive pulmonary disease: the COPE study.
Am J Respir Crit Care Med 2002,166(10):1358–1363.
Article
PubMed
Google Scholar
Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary diseasehttp://www.goldcopd.com/Guidelineitem.asp?l1=2&l2=1&intId=9892006.
Rabe KF, Hurd S, Anzueto A, Barnes PJ, Buist SA, Calverley P, Fukuchi Y, Jenkins C, Rodriguez-Roisin R, van Weel C, Zielinski J: Global Strategy for the Diagnosis, Management, and Prevention of Chronic Obstructive Pulmonary Disease: GOLD Executive Summary.
Am J Respir Crit Care Med 2007,176(6):532–555.
Article
PubMed
Google Scholar
Chronic obstructive pulmonary disease. National clinical guideline on management of chronic obstructive pulmonary disease in adults in primary and secondary careThorax 2004,59(Suppl 1):1–232.
Nayak AS, Banov C, Corren J, Feinstein BK, Floreani A, Friedman BF, Goldsobel A, Gottschlich GM, Hannaway PJ, Lampl KL, Lapidus RJ, Lawrence M, Lumry W, Munk Z, Pearlman D, Scardella AT, Schenkel EJ, Segal AT, Segall N, Silverman B, Shneyer L, Nolop KB, Harrison JE: Once-daily mometasone furoate dry powder inhaler in the treatment of patients with persistent asthma.
Ann Allergy Asthma Immunol 2000,84(4):417–424.
Article
CAS
PubMed
Google Scholar
Noonan M, Karpel JP, Bensch GW, Ramsdell JW, Webb DR, Nolop KB, Lutsky BN: Comparison of once-daily to twice-daily treatment with mometasone furoate dry powder inhaler.
Ann Allergy Asthma Immunol 2001,86(1):36–43.
Article
CAS
PubMed
Google Scholar
D'Urzo A, Karpel JP, Busse WW, Boulet LP, Monahan ME, Lutsky B, Staudinger H: Efficacy and safety of mometasone furoate administered once-daily in the evening in patients with persistent asthma dependent on inhaled corticosteroids.
Curr Med Res Opin 2005,21(8):1281–1289.
Article
PubMed
Google Scholar
Karpel JP, Busse WW, Noonan MJ, Monahan ME, Lutsky B, Staudinger H: Effects of mometasone furoate given once daily in the evening on lung function and symptom control in persistent asthma.
Ann Pharmacother 2005,39(12):1977–1983.
Article
CAS
PubMed
Google Scholar
Fish JE, Karpel JP, Craig TJ, Bensch GW, Noonan M, Webb DR, Silverman B, Schenkel EJ, Rooklin AR, Ramsdell JW, Nathan R, Leflein JG, Grossman J, Graft DF, Gower RG, Garay SM, Frigas E, Degraff AC, Bronsky EA, Bernstein DI, Berger W, Shneyer L, Nolop KB, Harrison JE: Inhaled mometasone furoate reduces oral prednisone requirements while improving respiratory function and health-related quality of life in patients with severe persistent asthma.
J Allergy Clin Immunol 2000,106(5):852–860.
Article
CAS
PubMed
Google Scholar
Standardization of Spirometry, 1994 Update. American Thoracic SocietyAm J Respir Crit Care Med 1995,152(3):1107–1136.
Crapo RO: Reference values for lung function tests.
Respir Care 1989, 34:626–637.
Google Scholar
Calverley P, Pauwels R, Vestbo J, Jones P, Pride N, Gulsvik A, Anderson J, Maden C: Combined salmeterol and fluticasone in the treatment of chronic obstructive pulmonary disease: a randomised controlled trial.
Lancet 2003,361(9356):449–456.
Article
CAS
PubMed
Google Scholar
Calverley PM, Boonsawat W, Cseke Z, Zhong N, Peterson S, Olsson H: Maintenance therapy with budesonide and formoterol in chronic obstructive pulmonary disease.
Eur Respir J 2003,22(6):912–919.
Article
CAS
PubMed
Google Scholar
Pauwels RA, Lofdahl CG, Laitinen LA, Schouten JP, Postma DS, Pride NB, Ohlsson SV: Long-term treatment with inhaled budesonide in persons with mild chronic obstructive pulmonary disease who continue smoking. European Respiratory Society Study on Chronic Obstructive Pulmonary Disease.
N Engl J Med 1999,340(25):1948–1953.
Article
CAS
PubMed
Google Scholar
Calverley PM, Anderson JA, Celli B, Ferguson GT, Jenkins C, Jones PW, Yates JC, Vestbo J: Salmeterol and fluticasone propionate and survival in chronic obstructive pulmonary disease.
N Engl J Med 2007,356(8):775–789.
Article
CAS
PubMed
Google Scholar
Scanlon PD, Connett JE, Waller LA, Altose MD, Bailey WC, Buist AS: Smoking cessation and lung function in mild-to-moderate chronic obstructive pulmonary disease. The Lung Health Study.
Am J Respir Crit Care Med 2000,161(2 Pt 1):381–390.
Article
CAS
PubMed
Google Scholar
Burge PS, Calverley PM, Jones PW, Spencer S, Anderson JA: Prednisolone response in patients with chronic obstructive pulmonary disease: results from the ISOLDE study.
Thorax 2003,58(8):654–658.
Article
CAS
PubMed
PubMed Central
Google Scholar
Chaudhuri R, Livingston E, McMahon AD, Thomson L, Borland W, Thomson NC: Cigarette smoking impairs the therapeutic response to oral corticosteroids in chronic asthma.
Am J Respir Crit Care Med 2003,168(11):1308–1311.
Article
PubMed
Google Scholar
Ito K, Ito M, Elliott WM, Cosio B, Caramori G, Kon OM, Barczyk A, Hayashi S, Adcock IM, Hogg JC, Barnes PJ: Decreased histone deacetylase activity in chronic obstructive pulmonary disease.
N Engl J Med 2005,352(19):1967–1976.
Article
CAS
PubMed
Google Scholar
Jones PW, Willits LR, Burge PS, Calverley PM: Disease severity and the effect of fluticasone propionate on chronic obstructive pulmonary disease exacerbations.
Eur Respir J 2003,21(1):68–73.
Article
CAS
PubMed
Google Scholar
Szafranski W, Cukier A, Ramirez A, Menga G, Sansores R, Nahabedian S, Peterson S, Olsson H: Efficacy and safety of budesonide/formoterol in the management of chronic obstructive pulmonary disease.
Eur Respir J 2003,21(1):74–81.
Article
CAS
PubMed
Google Scholar
Calverley PM, Spencer S, Willits L, Burge PS, Jones PW: Withdrawal from treatment as an outcome in the ISOLDE study of COPD.
Chest 2003,124(4):1350–1356.
Article
PubMed
Google Scholar
Spencer S, Calverley PM, Burge PS, Jones PW: Impact of preventing exacerbations on deterioration of health status in COPD.
Eur Respir J 2004,23(5):698–702.
Article
CAS
PubMed
Google Scholar
Wouters EF, Postma DS, Fokkens B, Hop WC, Prins J, Kuipers AF, Pasma HR, Hensing CA, Creutzberg EC: Withdrawal of fluticasone propionate from combined salmeterol/fluticasone treatment in patients with COPD causes immediate and sustained disease deterioration: a randomised controlled trial.
Thorax 2005,60(6):480–487.
Article
CAS
PubMed
PubMed Central
Google Scholar
Scanlon PD, Connett JE, Wise RA, Tashkin DP, Madhok T, Skeans M, Carpenter PC, Bailey WC, Buist AS, Eichenhorn M, Kanner RE, Weinmann G: Loss of bone density with inhaled triamcinolone in Lung Health Study II.
Am J Respir Crit Care Med 2004,170(12):1302–1309.
Article
PubMed
Google Scholar
Wedzicha JA, Calverley PM, Seemungal TA, Hagan G, Ansari Z, Stockley RA: The prevention of chronic obstructive pulmonary disease exacerbations by salmeterol/fluticasone propionate or tiotropium bromide.
Am J Respir Crit Care Med 2008,177(1):19–26.
Article
CAS
PubMed
Google Scholar
Calverley PM, Lee A, Towse L, van Noord J, Witek TJ, Kelsen S: Effect of tiotropium bromide on circadian variation in airflow limitation in chronic obstructive pulmonary disease.
Thorax 2003,58(10):855–860.
Article
CAS
PubMed
PubMed Central
Google Scholar